$150M Series B Fuels Curative’s National Expansion, Cementing Its Unicorn Status

Curative’s latest funding round marks a striking moment in the long struggle to fix American health insurance. Less than three years after launching its employer-based plan, the company has closed a $150 million Series B , securing a $1.275 billion valuation and officially entering unicorn territory. But what makes the story compelling isn’t just the number — it’s the company’s bet that health insurance can be rebuilt from the ground up, with AI at the center and zero out-of-pocket costs as the default.

Curative’s origins sit in a familiar frustration: a system defined by rising premiums, confusing benefits, and misaligned incentives across the traditional BUCA insurers. Instead of redesigning around the edges, Curative chose a first-principles approach. Its model asks members to complete one preventive “Baseline Visit,” after which they receive no deductibles, no co-pays, and no coinsurance . The idea sounds radical, but the early results — higher primary care engagement, lower hospitalizations, and reduced drug spending — gave the startup the leverage it needed to scale quickly.

That momentum drew in a high-profile roster of investors. Chris Anderson’s Upside Vision Fund led the round, while early backer Justin Mateen doubled down with a personal and JAM Fund investment of $47.5 million . Investors describe Curative as navigating one of the most complex industries with unusual speed and discipline, a rare combination in a market where even incremental innovation often stalls.

With fresh capital, Curative is shifting from regional disruptor to national player. The company plans to expand beyond its current base in Texas, Florida, and Georgia, moving into the Mid-Atlantic while strengthening the regulatory reserves required of a full-fledged insurer. At the same time, it’s investing heavily in AI-driven operations, member support, and a redesigned network model anchored by its new Curative Cash Card , which gives members access to care without surprise bills and pays providers instantly.

For industry watchers, the timing feels consequential. The pressure on employers, the inefficiency embedded in legacy networks, and the demand for predictable costs have all converged into a moment ripe for change. Curative’s bet is that a simpler, incentive-aligned system — one that makes people healthier while reducing friction — can scale to millions. Whether it becomes a model for the future or a bold outlier, the company has now secured the capital, the traction, and the attention to test that thesis at national scale.

Sources:
Yahoo! Finance
Bloomberg Law

A.M.